Oncology Real-World Data (RWD) & Trial Intelligence Software Directory

Oncology Real-World Data (RWD) & Trial Intelligence tools address a specific gap: oncology development teams need patient-level evidence that registries, single-site datasets, and claims alone cannot deliver. Sponsors use these platforms to identify eligible patients for narrow biomarker-defined trials, reconstruct lines of therapy from messy EHR narratives, benchmark outcomes against synthetic control arms, and answer payer questions post-launch. The operational tensions are well known to buyers — unstructured pathology and radiology text must be abstracted at scale, biomarker and NGS results must be linked across labs, and data use agreements with provider networks shape which cohorts are actually addressable. Workflows typically span clinical development, medical affairs, and commercial teams, each with different latency and granularity needs.

Two patterns stand out in the current landscape. Deployment is overwhelmingly cloud or SaaS, with only a small share offering hybrid models — a reflection of how centrally the underlying curated datasets are managed rather than a buyer preference. AI and ML adoption is high, with roughly three quarters of the category applying NLP or model-based abstraction to oncology records, which is consistent with how much of the relevant signal sits in unstructured notes. HIPAA coverage is common while GDPR appears in around a third of offerings, signaling that European cohort access remains a narrower segment of the market.